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Prolonged viral replication and longitudinal viral dynamic
differences among respiratory syncytial virus infected infants
Monica E Brint1,4, Joshua M Hughes2,4, Aditya Shah3, Chelsea R Miller3, Lisa G Harrison1, Elizabeth A Meals1,
Jacqueline Blanch1, Charlotte R Thompson3, Stephania A Cormier1 and John P DeVincenzo3

BACKGROUND: Longitudinal respiratory syncytial virus (RSV)
dynamics have not been well studied despite the existence of
factors favoring prolonged RSV replication including high
mutation rates allowing rapid evolution and potential escape
from immune control. We therefore measured viral load in
previously RSV-naive infants over prolonged time spans.
METHODS: During 2014–2015, quantitative nasal aspirates
were collected from 51 RSV-PCR+ infants. Multiple parallel
assessments of viral loads were quantified at each collected
time point using a well-validated real-time quantitative
reverse transcriptase polymerase chain reaction assay. After
observing viral load rebound phenomenon in some infants,
the viral dynamics of 27 infants with sufficient longitudinal
viral load data points were analyzed using the pre-defined
criteria for viral rebound. Additional analyses were performed
comparing age with viral rebound, viral clearance rates, and
viral load area-under-the-curve (AUCVL).
RESULTS: The 51 infants (303 nasal aspirate samples; mean of
5.9 per patient) exhibited slower than expected viral clearance.
Lower age trended toward slower viral clearance and greater
AUCVL. Six infants had detectable viral loads ≥ 1 month after
symptom onset. Ten of twenty-seven evaluable subjects
exhibited viral rebound and this rebound was age-dependent
(P = 0.0259). All but one rebounder were o70 days old.
CONCLUSION: Infants struggle to control primary RSV
infections allowing prolonged viral replication and previously
undescribed viral rebound; likely representing viral mutational
immune escape.

R

espiratory syncytial virus (RSV) is the most common
cause of lower respiratory tract infections in children and
has no available vaccine or antiviral treatments (1). Although
prematurity, immunodeficiency, chronic lung disease, and
congenital heart disease are risk factors for severe RSV
infections, the majority of children hospitalized for RSV are
previously healthy, the major risk factor being young
infant age (2). We have shown that higher mean viral loads
correlate with greater disease severity and longer duration of

hospitalization and symptoms (3–6). Young infants naturally
infected with RSV have exhibited more prolonged viral
shedding than their older counterparts (7). Properly performed viral culture can quantify replication-competent RSV,
but it is a relatively insensitive test compared to PCR (8) and
various factors elaborated within nasal secretions can
neutralize culturable virus within those secretions (1,9).
Because RSV RNA is rapidly eliminated when RSV replication
is effectively inhibited (10), a better tool to measure the actual
viral replication appears to be quantifying RSV RNA species.
We chose to quantify the RSV N gene in this investigation.
Furthermore, systematic longitudinal assessments of infant’s
viral loads have not previously been determined for longer
than 3 days using real-time quantitative reverse transcriptase
polymerase chain reaction (qRT-PCR) (11). In order to better
understand the pathogenesis of RSV, we sought to describe
the viral dynamics of RSV in infants over an extended time
period. Therefore, from December 2014 to April 2015, the
nasal aspirates of 51 naturally infected infants were quantitatively collected. The viral loads of these samples were
measured with qRT-PCR during hospitalization and during
multiple longitudinal follow-up outpatient visits for up to
1 month thereafter.
METHODS
Subjects and Study Design
Fifty-one naturally infected, hospitalized infants (o1-year old)
were enrolled after laboratory-confirmed RSV infection during the
December 2014-April 2015 RSV season. In order to study viral
clearance in previously healthy infants, subjects who had known
bacteremia, immunodeficiency, hemodynamically significant congenital heart disease, previous oxygen use for 47 days, or had ever
received corticosteroids, antiviral agents or palivizumab (Synagis,
MedImmune, Gaithersburg, MD, USA) were excluded. The conduct
of this research followed the University of Tennessee Health Science
Center Institutional Review Board guidelines including appropriate
informed consent.
Sample Collection
Nasal aspirate samples were collected daily during hospitalization
and serially after discharge during study-specific visits on select days
for up to 1 month after study enrollment. The scheduled study visits
for sample collection include days 1, 2, 3, 4, 5, 7, 9, 11, 13, 15, 21, and
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28. Study-specific visits were scheduled and accomplished regardless
of the subject’s clinical symptoms. If a subject missed their scheduled
visit, arrangements were made to collect the sample within 1–2 days
of their scheduled collection time. Samples were collected by trained,
study-specific personnel using a standardized quantitative method as
previously described (4). All subject information was removed;
samples were assigned a designated lab number in order to blind
study personnel during qRT-PCR assays.
Due to variable duration of hospitalization among subjects and
loss to follow-up as outpatients, there was a lack of uniformity in the
quantity of samples collected from different individuals. Parents of
the subjects reported the onset of their child’s symptoms during the
initial study enrollment visit. The earliest onset of any associated
symptom was used to normalize the timing of sample collection. The
associated symptoms considered were fever, nasal congestion,
coughing, and increased work of breathing.
Viral RNA Extraction and Real-Time qRT-PCR
A 200 μl aliquot from the nasal aspirate sample was RNA extracted
using an EZ1 Virus Minikit v2.0 and an automated EZ1 Advanced
XL machine (Qiagen, Valencia, CA). Reverse transcription and a
TaqMan-based real-time qRT-PCR assay was performed using the
ABI Prism 7900HT and 7500Fast systems (Applied Biosystems
International, Foster City, CA) (11). The qRT-PCR results were
quantified using six duplicate-well, 10-fold dilution internal standard
curves of identical micro-aliquots of quantitatively cultured RSV-A
and RSV-B whole virus. The qRT-PCR results were reported as Log10
plaque-forming unit equivalents per milliliter (Log PFUe/ml) (11).
The qRT-PCR was performed in duplicate for each nasal aspirate
sample, and separate runs were performed using custom primers
specific for RSV-A and RSV-B subtypes (11). Additional second runs
using this identical technique were performed. One of the RSV-Aspecific qRT-PCR runs failed, and limited sample volume prevented
repeating the run. RSV-B-specific qRT-PCR results were reported as
the geometric mean across all four individual wells from these two
runs (Figure 1). The mean viral loads of the two runs were compared
(Figure 2).
Inter-Subject Consistency of Real-Time qRT-PCR Results
Following reverse transcription, the nasal aspirate sample’s cDNA
was run in duplicate wells in the qRT-PCR assay (Figure 2). The
detected viral loads from these duplicate wells were compared
to determine the inter-sample reproducibility of the assay,
showing minimal variability (R2 = 0.996, Figure 2a). For further
determination of viral load measurement consistency, the mean viral
loads from qRT-PCR runs 1 and 2 were compared. This analysis also
showed a strong correlation between the two runs (R2 = 0.9234,
Figure 2b). This run-to-run analysis was only performed for the
qRT-PCR assay using the RSV-B primers, because the second RSV-A
run failed, leaving insufficient sample remaining.
Analysis of Viral Load and Definition of Viral Load Rebound
Enrolled subjects were evaluated for those having sufficient sample
collections for longitudinal analysis as follows: nasal aspirate samples
must have been collected for ≥ 5 time points and ≥ 2 of those time
points must have occurred beyond the 8th day after symptom onset.
Twenty-seven subjects had sufficient longitudinal data. Before any
data analysis was initiated, we defined criteria for viral load rebound
as follows: a decrease in viral load over a course of ≥ 2 time points
before viral load nadir, the nadir must have occurred after day 8 of
symptom onset, and an increase in viral load following the nadir
must have occurred over ≥ 2 time points, with 1 of those being ≥ 1
Log PFUe/ml greater than the nadir.
Analysis of Viral Load Clearance
The viral load area-under-the-curve (AUCVL, Log PFUe × days/ml)
was calculated for the 27 longitudinally evaluable subjects. Viral load
clearance within the first 48 h of study enrollment was determined by

Copyright © 2017 International Pediatric Research Foundation, Inc.

|

Articles

calculating the slope within that time frame. Of the 51 subjects, 40
subjects had sufficient samples for slope evaluation.
Statistical Analysis
Statistical analyses and figure construction were performed with
GraphPad Prism Software v7.0 (La Jolla, CA). Variability between
duplicate wells and separate qRT-PCR assay runs, as well as
comparisons of age to AUC and viral clearance slopes were
performed using linear regression. The subjects’ ages (chronological
and post conceptional) were normally distributed, and were
compared to the presence of viral load rebound using unpaired ttests. The AUC and viral clearance slopes were also compared to the
presence of rebound using unpaired t-tests. Two-sided α of o0.05
were considered statistically significant.

RESULTS
Characteristics of Study Population

Subject characteristics were determined for both the entire
data set of 51 subjects, as well as a subset of 27 subjects with
sufficient data for individual longitudinal analysis (Table 1).
The mean age of subjects at enrollment was 98.39 ± 81.82
(mean ± SD) days and 94.22 ± 76.26 days for the n = 51 and
n = 27 data sets, respectively. On the basis of local RSV
seasonality, ages, lack of previous respiratory hospitalization,
and other subject history, all study subjects were enrolled
during their first RSV season and therefore were likely
experiencing their first RSV infection.
Viral Persistence of Enrolled Subjects

The 51 enrolled subjects were sampled for 301 separate times
(mean 5.9 samples/subject), and the mean length of time over
which samples were collected was 17.29 days after symptom
onset. First sample collection occurred at a mean of 3 days
after symptom onset. Ten of the subjects were only available
for collection for o7 days. Of the infants with sufficient data
collection at or after the representative time points, 39 of 41
(95%) were still RSV+ at 1 week, 22 of 26 (85%) at 2 weeks,
and 6 of 16 (38%) at 1 month after symptom onset
(Figure 3a). The mean viral loads for each subject were
individually analyzed for viral clearance (Δviral load/Δtime)
kinetics.
Viral Load and Viral Dynamics

Prior to data analysis and unblinding, 27 of 51 subjects were
determined to have sufficient longitudinal points to analyze
for viral rebound effect (five minimum time points with two
or more time points occurring after day 8 of symptom onset).
Ten of these twenty-seven subjects exhibited viral load
rebound (defined in Methods section). An example of two
individual patient’s mean viral load curves, one exhibiting
rebound and the other without rebound, is shown in Figure 3.
Additional subjects’ individual viral load curves lacking viral
load rebound and exhibiting viral load rebound are shown in
Figures 4 and 5, respectively.
After the assignment of viral rebound subject classification,
the data were unblinded and the subjects’ characteristics at
enrollment were examined for association with viral load
rebound beginning with the subjects’ age at enrollment. The
Volume 82 | Number 5 | November 2017
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Quantitative nasal aspirate sample collection is
performed by trained lab professionals following a
standardized protocol.

Homogenize and mix nasal aspirate samples.

Aliquot nasal aspirate samples into 200 µl
aliquots using a sterile pipette.

Viral RNA extraction using EZ1 Virus Minikit v2.0 and
an automated EZ1 Advanced XL machine yields 60
µl of viral RNA

qRT-PCR Run-1

qRT-PCR Run-2

Reverse transcriptase step using RSV
subtype-specific primers and 12 µl
of viral RNA to yield 20 µl of cDNA.

Reverse transcriptase step using RSV
subtype-specific primers and 12 µl
of viral RNA to yield 20 µl of cDNA.

TaqMan-based real-time quantitative
reverse transcriptase polymerase chain
reaction (qRT-PCR) using a master PCR
mix with 5 µl of cDNA per well (×2).

TaqMan-based real-time quantitative
reverse transcriptase polymerase chain
reaction (qRT-PCR) using a master PCR
mix with 5 µl of cDNA per well (×2).

Well 1A

Well 2A

Well 1B

Well 2B

Figure 1. Study protocol for collecting and analyzing viral loads from nasal aspirate samples.

mean age of subjects with viral load rebound was significantly
lower than the mean age of subjects with no viral load
rebound (Figure 6; P = 0.0259). All but one infant who had
viral load rebound were o70 days of age (Figure 6). This
significant association persisted when adjusting for postconceptional age (sum of gestational age and age at initial
sample collection).
Viral Clearance

In order to investigate RSV clearance, the AUCVL of the 27
screened subjects was calculated. Potential correlations
between these AUCVL values with age at enrollment, as well
as with post-conceptional age were investigated. Lower age
was associated with higher AUCVL; however, this was not
significant (P = 0.2536). There was a significantly higher mean
AUC in the subjects who displayed viral rebound, compared
to those who did not (P = 0.0035). Of these 27 subjects, 8
(30%) had persistently detectable RSV at their last date of
collection. Six of these eight subjects exhibited viral load
rebound as previously described.
Viral clearance was also evaluated by analyzing the viral
load slope within the first 48 h of study enrollment for the 40
subjects with evaluable time points. This analysis was
performed in order to investigate a potential relationship
874 Pediatric RESEARCH
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between poor initial viral clearance and the presence of viral
load rebound. Linear regression analysis was performed
between viral clearance and age at enrollment, gestational
age, as well as post-conceptional age as done with the AUCVL
analysis. These analyses showed a trend toward more rapid
viral clearance with increasing age at enrollment and postconceptional age; however, these findings were not significant
(P = 0.4019 and 0.6140, respectively). Additionally, there was
no significant association between the viral clearance slopes
within the first 48 h of study enrollment and the presence of
viral load rebound (P = 0.1395).
DISCUSSION
We report the first longitudinal sampling and systematic
analysis of RSV load using modern molecular quantification
techniques in large numbers of previously healthy infants.
Several lines of evidence indicate real-time qRT-PCR reliably
measures active RSV replication. The first evidence is that
there is a very rapid lowering and disappearance of detectable
qRT-PCR viral load in RSV-infected subjects after dosing with
a potent RSV replication inhibitor (10). This shows RSV RNA
does not persist in respiratory secretions after viral replication
ceases. The second line of evidence is RSV mRNA can be
quantitatively detected in human RSV infections throughout
Copyright © 2017 International Pediatric Research Foundation, Inc.
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Figure 2. Evaluation of intrinsic variability in real-time quantitative
reverse transcriptase polymerase chain reaction (qRT-PCR) assay. (a) The
data points represent the mean viral load values (Log PFUe/ml) in
duplicate wells during run-2 for RSV-A- and RSV-B-specific assays
(Figure 1). Linear regression analysis showed that there was good
correlation between the log values in the duplicate wells (R2 = 0.9959).
(b) The data points represent the mean viral load values (Log PFUe/ml)
of duplicate wells (mean of Wells 1A and 1B, and mean of Wells 2A and
2B) from the two runs of RSV-B-specific assays (Figure 1). There was
good correlation between the mean well values between qRT-PCR run-1
and run-2 (R2 = 0.9234). No subject’s qRT-PCR result on any sample
switched from RSV-A to RSV-B nor from RSV-B to RSV-A.

the course of RSV qRT-PCR positivity even after culturenegativity occurs (9). The third line of evidence is that RSV
culture from respiratory secretion of humans can become
neutralized by the presence of antibodies within those
secretions, showing RSV culture techniques measure falsely
short durations of RSV replication (9,12). Thus, RSV qRTPCR is an accurate measure of true RSV replication.
A single previous study described higher maximum viral
loads occurring in hospitalized infants o1-month-old
compared to those over the age of 1 month during
1974–1975 RSV season (7). This age-related finding suggests
age may play a role in the initial viral load of naturally
infected infants. One subject remained culture positive until
Copyright © 2017 International Pediatric Research Foundation, Inc.
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their last collection time point at day 21 from their study
enrollment, which may have suggested prolonged viral clearance in young infants. However, the study did not address the
relative clearance kinetics of RSV in different age groups.
Despite some similar findings, this previous study differs
from ours in methodology, study subject characteristics, and
study design. Hall et al. (7) had a sample size of 23 subjects
compared to our longitudinal study’s sample size of 51 subjects.
The previous study only followed up subjects in the outpatient
setting if they were culture positive at hospital discharge. This
may have biased the sample collection towards those who had a
more severe infection and therefore required a longer duration
of hospitalization. The previous study did not specify the
number of subjects followed up in an outpatient setting until
the subjects became culture negative. To contrast, our study
collected an unbiased set of nasal aspirate samples during
hospitalization and after their hospital discharge. The previous
study did not collect nasal aspirate samples once the subject
was RSV negative. Our study performed qRT-PCR blindly on
all samples multiple times regardless of the predicted RSV
result and all subjects were contacted for follow-up visits after
hospital discharge according to our study visit schedule.
Whereas the previous study collected only seven total samples
after day 15 from enrollment, our longitudinal study collected
78 samples from 25 of 51 subjects at time points greater than
day 15 from symptom onset. The previous study’s methodology may have prevented Hall from evaluating clearance
kinetics and detecting viral load rebound especially considering
the threshold of detection of PCR is significantly better than
TCID50 culture quantification.
The longitudinal viral dynamics of RSV have not previously
been studied using qRT-PCR over time beyond the first few
days (6,11). In order to ensure longitudinal sample collections
were not influenced by viral load results, qRT-PCR was
performed on all samples 46 months after the 2014–2015
RSV season end. The subjects in this study were followed over
a much more extensive time period and 30% of evaluable
subjects showed detectable viral loads of ≥ 1 Log PFUe/ml at
28–35 days after symptom onset. Overall, the 51 enrolled
subjects exhibited very slow viral clearance kinetics. It was
previously thought that RSV was rapidly cleared by the
immune response within the first 1–2 weeks of symptom
onset (13). The prolonged presence of replicating virus in our
subjects suggests a delayed viral clearance in RSV-infected
infants. This newly recognized prolonged viral replication
corresponds well to previously recognized prolonged postacute symptoms and disease manifestations in RSV-infected
infants, including prolonged cough and pulmonary function
changes (14,15).
We also observed that a frequent component of delayed
viral clearance was viral load rebound occurring after the
earliest estimated initiation of cell-mediated immune
response, which generally first occurs around the 8th day of
exposure (16). Further examination of individual subjects’
viral load curves indicated that 10 of 27 (37%) analyzed
subjects expressed this rebound phenomenon. In order to
Volume 82 | Number 5 | November 2017
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Table 1. Study subject demographics
Study subjectsa (n = 51)

Subjects for rebound analysisb (n = 27)

n (%)

n (%)

Caucasian

13 (25.49)

6 (22.22)

African-American

Race
36 (70.59)

19 (70.37)

Hispanic

1 (1.96)

1 (3.70)

Other

1 (1.96)

1 (3.70)

32 (62.75)

17 (62.96)

Sex
Male
Female
Subjects requiring oxygen supplementation

19 (37.25)

10 (37.04)

36 (70.59)

16 (59.26)

Subjects In ICU

5 (9.80)

4 (14.81)

Subjects requiring mechanical ventilation

3 (5.88)

3 (11.11)

Subjects with family history of asthma

30 (58.82)

18 (66.67)

Subjects with family history of eczema

16 (31.37)

8 (29.63)
Study subject clinical characteristics

Mean (± SD)

IQR

Mean ( ± SD)

IQR

Age at admission (days)

98.39 ( ±81.82)

87

94.22 (±76.26)

116

Age at NW collection (days)

99.45 (±81.80)

86

95.30 (±76.18)

116

Gestational age (weeks)

37.53 (±2.33)

3

37.76 (±2.46)

Birth weight (g)

2873 (±725.3)

Hospital length of stay (days)

5.92 (±3.24)

3

6.70 (±4.08)

5

Duration of symptom onset (days)

4.14 (±2.00)

2

4.22 (±2.28)

2

899

2863 (±778.3)

4
850

Number of children in household

2.12(±1.63)

3

2.07 (±1.66)

2

Number of household members

5.08 (±1.72)

3

4.89 (±1.65)

2

ICU, intensive care unit; IQR, interquartile range; NW, nasal wash; SD, standard deviations.
a
Subjects who had known bacteremia, immunodeficiency, hemodynamically significant congenital heart disease, previous oxygen use for 47 days, or had ever received corticosteroids, antiviral agents, or palivizumab (Synagis) were excluded.
b
Represents those subjects that were preselected to have sufficient viral load data for longitudinal evaluation (see Methods).

reduce the probability of false classification of viral rebound
brought about by sampling or procedural variability, an
objective biologically based conservative definition of viral
load rebound was applied blindly to all 27 subjects who had
repeated measurements of viral load from quantitatively
collected samples. On the basis of the well-established
association of young infant age and severe RSV disease
(4,17), age at enrollment was evaluated with respect to those
showing viral load rebound (Figure 6). Because RSV infection
is so common during infancy, and because RSV exposure
occurs at different ages during infancy, this natural viral
infection can be uniquely used to interrogate the ontogeny of
the infant immune response. The significantly lower mean age
of subjects displaying viral load rebound suggests an agerelated functional maturation of infant cell-mediated antiviral
immune responses.
The possibility that a re-infection produced our observed
rebound phenomenon is extremely low. Within our individual subjects’ longitudinal sample collections, we observed no
switching of RSV subtype, based on subtype-specific probes to
876 Pediatric RESEARCH
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N-gene region, despite the high frequency of RSV-A and
RSV-B co-circulating within the 2014–2015 season’s epidemic
(Figure 2). In future studies, the potential presence of RSV
genotype switching within individual subjects might be
further explored by performing whole-genome deep sequencing on subjects’ longitudinal samples.
Viral clearance within the first 48 h was examined for
significant differences in initial antiviral immune responses.
There were no statistically significant correlations between
initial viral clearance and age or the presence of viral load
rebound. However, using the same assay, the viral load AUC
in naturally infected infants is statistically higher than in
adults who are experimentally infected with RSV (Po0.0001)
(5). Due to the complications of the viral load rebound
phenomena and eight subjects having detectable viral loads at
the last collection time point, the utility of evaluating viral
load AUC vs. host differences was difficult.
Our study had certain limitations. For instance, the subject
population for this study encompasses infants hospitalized with
RSV, but does not include infants encountering RSV in
Copyright © 2017 International Pediatric Research Foundation, Inc.
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Figure 3. Prolonged viral replication and viral load rebound. (a) Mean viral load of RSV-A and -B (± SEM) measured in log plaque-forming unit
equivalents per milliliter (Log PFUe/ml). Each data point represents the geometric mean viral load of nasal aspirate samples for a specific day from
symptom onset. The corresponding sample size is represented below each data point. (b) A representative individual subject viral load graph
showing no viral load rebound. (c) A representative individual subject viral load graph showing viral load rebound. The vertical dashed line on day 8
from symptom onset represents the estimated onset of the subject’s first cell-mediated immune response. The data points (filled circles) represent
the viral load for individual wells, and horizontal dashes represent the geometric mean viral load for a specific day from symptom onset.

outpatient and home environments. Although the disease
severity is clearly higher in hospitalized subjects, the study of
this subpopulation has clear clinical relevance. During the
course of study, frequent nasal aspirate samples were collected,
but due to a lack of existing validated symptom-scoring
instruments for outpatients the corresponding symptoms were
not able to be documented. In future studies, symptom scores
will be implemented alongside the sample collection to address
this issue. Additionally, there are logistical difficulties in
collecting symptom information because the subjects cannot
self-report their symptoms and there is not a validated method
Copyright © 2017 International Pediatric Research Foundation, Inc.

for parental reporting of their child’s symptoms. We have
recently shown through within-host longitudinal sampling and
whole-viral genome deep sequencing that RSV genome
diversity evolves directionally within a single RSV infection
in response to the institution of an infant immune response
(18). This diversity includes amino-acid sites within the second
hypervariable region of RSV-G, which is used for viral
genotype assignment. In future studies of this clinical cohort,
we plan to utilize whole-genome viral longitudinal within-host
deep sequencing to evaluate the mechanisms of the viral load
rebound phenomenon, examining whether viral diversity
Volume 82 | Number 5 | November 2017
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Figure 4. Individual subject viral load graphs showing lack of viral load rebound. Included in the figure are all subjects with sufficient data points for
longitudinal analysis. Subjects were excluded if they had fewer than five data points or had fewer than two data points occurring after day 8 from
symptom onset. The vertical dashed line on day 8 from symptom onset represents the estimated onset of the subject’s first cell-mediated immune
response. The data points (filled circles) represent the viral load for individual wells, and the horizontal dashes represent the geometric mean viral
load for a specific day from symptom onset.
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Figure 5. Individual subject viral load graphs showing viral load rebound. Included in the figure are all subjects with sufficient data points for
longitudinal analysis. Subjects were excluded if they had fewer than five data points or had fewer than two data points occurring after day 8 from
symptom onset. The vertical dashed line on day 8 from symptom onset represents the estimated onset of the subject’s first cell-mediated immune
response. The data points (filled circles) represent the viral load for individual wells, and the horizontal dashes represent the geometric mean viral
load for a specific day from symptom onset.

during rebound occurs at recognized T- and B-cell epitope sites
(19). Additionally, the future deep genome sequence analysis of
the second hypervariable region of G protein in our study
samples may allow us to distinguish between immune escape
mutations in the original RSV infection and the presence of a
second RSV infection.
Past studies have shown that there is a link between severe
RSV infections in early life and the development of chronic
wheezing and asthma (20). Future investigations of the
relationship between prolonged viral load presence and
Copyright © 2017 International Pediatric Research Foundation, Inc.

chronic wheezing would provide further insight into the
clinical relevance of prolonged viral replication and viral load
rebound. This analysis may also be paired with the evaluation
of immune response differences in infants with delayed viral
clearance.
In conclusion, RSV replicates more extensively than
previously recognized in infants and much longer than adults.
Viral load rebound is frequent among subjects and especially
in those displaying delayed viral load clearance. This
phenomenon of viral load rebound was not previously
Volume 82 | Number 5 | November 2017
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Figure 6. Age at study enrollment and viral load rebound. Mean age
( ± SD) at study enrollment for 27 screened subjects (subjects with viral
load rebound, 56.2 ±14.07 days (n = 10); subjects with no viral load
rebound, 127.5 ± 21.4 days (n = 17); P = 0.0259). Each data symbol
represents an individual subject’s age at study enrollment. Following
evaluation for Gaussian distribution using a D’Agostino Normality test,
an unpaired t-test (two-tailed) was performed to compare the mean
ages between the subjects with viral load rebound and the subjects
with no viral load rebound; *P = 0.0259.

described in any acute viral illness and appears to be
occurring after the initiation of cell-mediated immune
responses, in an age-dependent manner. Establishing the
mechanisms and clinical relevance of prolonged viral
replication and viral load rebound will help us to understand
RSV disease pathogenesis. Our findings have clear relevance
to the development of antiviral therapies, potentially
strengthening their utility in a clinical setting.
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